- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06154408
Evaluating the Impact of Omega-3 Fatty Acid Supplementation (Soloways™) on Lipid Profiles in Adults With PPARG Polymorphisms (SOLIPARG)
Evaluating the Impact of Omega-3 Fatty Acid Supplementation (Soloways™) on Lipid Profiles in Adults With PPARG Polymorphisms: A Randomized, Double-blind, Placebo-controlled Trial
In this study, 102 patients will be evenly randomized into two groups: one set to receive omega-3 fatty acids and the other a placebo. The process will be blinded, ensuring that neither the researchers nor the participants will know which group they are in. Each participant will take two capsules daily for a duration of 90 days, with the active group receiving capsules containing 1000 mg of fish oil each. All participants will be instructed to maintain their usual diet, lifestyle, and medication regimen.
At the beginning and end of the study, various health assessments, including lipid panels and C-reactive protein measurements, will be conducted. Additionally, DNA samples will be collected for genotyping to identify patients with specific PPARG gene polymorphisms, leading to the creation of four distinct subgroups: those receiving omega-3 with and without polymorphisms, and those receiving placebo with and without polymorphisms.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Novosibisk Region
-
Novosibirsk, Novosibisk Region, Russian Federation, 630090
- Center of New Medical Technologies
-
Contact:
- Andrei AV Ponomarenko, MD
- Phone Number: +79628316017
- Email: dayshadoff@gmail.com
-
Contact:
- Elena EI Krykova
- Phone Number: +79133825952
- Email: krukova_ei@cnmt.ru
-
Principal Investigator:
- Eugene EA Pokushalov, PhD
-
Sub-Investigator:
- Andrei AV Ponomarenko, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age between 40 and 75;
- ( LDL-C level between 70 and 190 mg/dL, confirmed in at least two sequential checks conducted within the last six months prior to signing the consent form.
Exclusion Criteria:
- Personal history of cardiovascular disease or hight risk (≥ 20%);
- Triglycerides (TG) ≥ 400 mg/dL;
- Obesity (Body Mass Index > 32 kg/m2);
- Assumption of lipid-lowering drugs or supplements affecting lipid metabolism within the last three months;
- Diabetes mellitus;
- Known severe or uncontrolled thyroid, liver, renal, or muscle diseases.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: placebo group
|
placebo capsules identical in appearance, matched for color coating, shape, and size with omega-3 fatty acids capsule
|
Experimental: omega-3 fatty acids group
|
The active treatment, supplied by Soloways, LLC., contained omega-3 fatty acids (1000 mg of fish oil, of which 600 mg were eicosapentaenoic acid and 300 mg docosahexaenoic acid) per capsule.
The subjects will take 2 capsules daily.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the percent change in LDL-C for omega-3 fatty acids among patients with PPARG polymorphism
Time Frame: 90 days
|
the percent change in LDL-C for omega-3 fatty acids compared with placebo among patients with PPARG polymorphism
|
90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the percent change in hsCRP
Time Frame: 90 days
|
the percent change in hsCRP for omega-3 fatty acids compared with placebo among patients with PPARG polymorphism
|
90 days
|
the percent change in High-density lipoprotein cholesterol
Time Frame: 90 days
|
the percent change in High-density lipoprotein cholesterol for omega-3 fatty acids compared with placebo among patients with PPARG polymorphism
|
90 days
|
the percent change in total cholesterol the percent change in total cholesterol
Time Frame: 90 days
|
the percent change in total cholesterol for omega-3 fatty acids compared with placebo among patients with PPARG polymorphism
|
90 days
|
the percent change in serum triglycerides
Time Frame: 90 days
|
the percent change in serum triglycerides for omega-3 fatty acids compared with placebo among patients with PPARG polymorphism
|
90 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SW001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on LDL Hyperlipoproteinemia
-
Saint-Joseph UniversityUnknownDyslipidemias | LDL HyperlipoproteinemiaLebanon
-
Nina HermansUniversity Hospital, AntwerpRecruitingLow-Density-Lipoprotein-Type [LDL] HyperlipoproteinemiaBelgium
-
Iuliu Hatieganu University of Medicine and PharmacyCompletedWeight Loss | Glucose, High Blood | LDL Hyperlipoproteinemia | HDL | Triglycerides High
-
Yonsei UniversityDaewoong Pharmaceutical Co. LTD.RecruitingLow-Density-Lipoprotein-Type [LDL] HyperlipoproteinemiaKorea, Republic of
-
Alnylam PharmaceuticalsCompletedElevated LDL-Cholesterol (LDL-C)United Kingdom
-
LIB Therapeutics LLCMedpace, Inc.CompletedLDL CholesterolUnited States
-
Universidad de GranadaUniversity of Copenhagen; University of Oxford; Harvard University; University... and other collaboratorsRecruiting
-
Uppsala UniversityDalarna County Council, SwedenCompleted
-
Unity Health TorontoUnknown
-
University of Texas Southwestern Medical CenterMerck Sharp & Dohme LLC; Donald W. Reynolds FoundationCompletedCholesterol, LDLUnited States
Clinical Trials on omega-3 fatty acids
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedBreast Neoplasms | ArthralgiaUnited States
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaboratorsCompleted
-
Wen-Chih WuWithdrawnSteatosis | Right Ventricular Failure | Pulmonary; HypertensionUnited States
-
University of California, San FranciscoAutism SpeaksCompleted
-
Pennington Biomedical Research CenterCompleted
-
Evandro Chagas Institute of Clinical ResearchAndrea Silvestre de Sousa, MD PhD; Pedro Emmanuel Alvarenga Americano do Brasil... and other collaboratorsCompletedChagas CardiomyopathyBrazil
-
Hugo W. Moser Research Institute at Kennedy Krieger...University of California, San FranciscoCompletedAutism Spectrum Disorders | HyperactivityUnited States
-
Retina Foundation of the SouthwestDSM Nutritional Products, Inc.CompletedInfant DevelopmentUnited States
-
Centre for Chronic Disease Control, IndiaCompleted
-
Shanghai Mental Health CenterHarbin Medical University; Qingdao Mental Health CenterRecruitingBipolar Disorder | Major Depressive Disorder | Omega-3 Fatty AcidsChina